Table 4 Patient-level factors associated with receiving low-dose rivaroxaban from the Veterans Health Administration, as compared to receiving full-dose, among those who met clinical criteria to receive full-dose rivaroxaban for non-valvular atrial fibrillation (n = 16,831)

 ≤ 69

22.9%

53.8%

REF

 70–74

16.1%

22.3%

1.61

(1.32, 1.97)

<  0.001

 75–79

16.7%

11.8%

2.80

(2.26, 3.45)

<  0.001

 >  80

44.2%

12.1%

5.77

(4.78, 6.97)

<  0.001

 Female

2.0%

1.6%

1.71

(1.06, 2.65)

0.02

 Male

98.0%

98.4%

REF

 White

86.4%

85.2%

REF

 Black

7.0%

8.9%

0.99

(0.76, 1.28)

0.93

 Other

6.5%

5.9%

1.21

(0.91, 1.57)

0.18

 Northeast

15.6%

13.7%

REF

 Midwest

26.8%

25.8%

1.14

(0.91, 1.42)

0.25

 West

20.0%

19.8%

1.14

(0.90, 1.44)

0.28

 South

37.6%

40.7%

0.98

(0.80, 1.21)

0.85

 <  25

14.6%

12.5%

REF

 25–29.9

35.1%

30.6%

1.51

(1.22, 1.87)

<  0.001

 30–34.9

27.9%

28.8%

2.26

(1.80, 2.85)

<  0.001

 ≥ 35

20.1%

26.3%

2.53

(1.97, 3.25)

<  0.001

 Heart Failure

19.4%

14.1%

1.48

(1.23, 1.78)

<  0.001

 Hypertension

78.4%

72.3%

1.09

(0.91, 1.32)

0.35

 Vascular Disease

17.1%

17.5%

0.88

(0.73, 1.06)

0.18

 Diabetes

51.8%

48.5%

1.05

(0.90, 1.23)

0.52

 Prior Bleeding

3.4%

3.5%

0.88

(0.61, 1.25)

0.50

 Stroke

8.5%

6.5%

1.27

(0.99, 1.61)

0.058

 50–59

48.6%

7.6%

8.40

(7.16, 9.85)

<  0.001

 >  60

51.4%

92.4%

REF

 0–2

22.2%

28.3%

REF

 3–4

38.3%

38.3%

1.27

(1.05, 1.53)

0.02

 ≥ 5

32.6%

27.2%

1.80

(1.43, 2.27)

<  0.001